Trials / Unknown
UnknownNCT05146843
The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients
The Impact of Chronic Mitochondrial Antioxidant (MitoQ) Supplementation on Cardiovascular Toxicity Induced by Doxorubicin-Based Adjuvant Chemotherapy in Breast Cancer Patients: Randomized Clinical Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- D'Or Institute for Research and Education · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Investigate the protective effect of chronic MitoQ supplementation on cardiovascular toxicity induced by doxorubicin-based adjuvant chemotherapy in breast cancer patients.
Detailed description
Test the hypothesis that chronic MitoQ supplementation in breast cancer patients treated with doxorubicin prevents: 1. increased mitochondrial oxidative stress; 2. the increase in cardiac markers (B-type natriuretic peptide and troponin I); 3. changes in left ventricular deformity (speckle tracking, strain) and reduction in LVEF; 4. endothelium-dependent dysfunction of peripheral vascular beds; 5. the increase in endothelial microvesicles; 6. the increase in material stiffness; 7. the elevation of central blood pressure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mitoquinone | Mitoquinone pill, 20 mg/day |
| OTHER | Placebo | Placebo pill, 20 mg/day |
Timeline
- Start date
- 2022-06-02
- Primary completion
- 2022-11-01
- Completion
- 2023-12-02
- First posted
- 2021-12-07
- Last updated
- 2022-04-08
Source: ClinicalTrials.gov record NCT05146843. Inclusion in this directory is not an endorsement.